Literature DB >> 31305869

Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.

Karin P Miller1, Girish Venkataraman2, Christopher D Gocke1, Denise A Batista1, Michael J Borowitz1, Kathleen H Burns1, Keith Pratz3, Amy S Duffield1.   

Abstract

OBJECTIVES: Increasingly, acute promyelocytic leukemia (APL) is treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This study characterizes bone marrow findings after ATRA/ATO therapy.
METHODS: Bone marrow biopsies from 16 patients treated with ATRA/ATO and seven patients treated with ATRA/chemotherapy (CTX) for APL were evaluated.
RESULTS: In ATRA/ATO cases, the marrow was likely to be hypercellular (79%) with a decreased myeloid:erythroid (M:E) ratio (88%), megaloblastoid maturation of erythroid precursors (100%), erythroid atypia (75%), and increased (88%) and atypical (75%) megakaryocytes. Significant myeloid atypia was only seen in extensive residual disease. The ATRA/CTX cases were less likely to be hypercellular (38%), have a M:E ratio of 1:1 or less (0%), exhibit significant erythroid atypia (0%), or have increased (0%) or atypical (38%) megakaryocytes.
CONCLUSIONS: Bone marrow biopsies from patients treated with ATO have unusual but characteristic features. Despite variability in marrow findings, clinical outcomes were uniformly favorable. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Acute promyelocytic leukemia; All-trans retinoic acid; Arsenic trioxide

Year:  2019        PMID： 31305869      PMCID： PMC6779253          DOI： 10.1093/ajcp/aqz087

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  22 in total

Review 1.  Current standard treatment of adult acute promyelocytic leukaemia.

Authors:  Francesco Lo-Coco; Laura Cicconi; Massimo Breccia
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

2.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Authors:  Uwe Platzbecker; Giuseppe Avvisati; Laura Cicconi; Christian Thiede; Francesca Paoloni; Marco Vignetti; Felicetto Ferrara; Mariadomenica Divona; Francesco Albano; Fabio Efficace; Paola Fazi; Marco Sborgia; Eros Di Bona; Massimo Breccia; Erika Borlenghi; Roberto Cairoli; Alessandro Rambaldi; Lorella Melillo; Giorgio La Nasa; Walter Fiedler; Peter Brossart; Bernd Hertenstein; Helmut R Salih; Mohammed Wattad; Michael Lübbert; Christian H Brandts; Mathias Hänel; Christoph Röllig; Norbert Schmitz; Hartmut Link; Chiara Frairia; Enrico Maria Pogliani; Claudio Fozza; Alfonso Maria D'Arco; Nicola Di Renzo; Agostino Cortelezzi; Francesco Fabbiano; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Sergio Amadori; Franco Mandelli; Gerhard Ehninger; Richard F Schlenk; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.

Authors:  J Zhu; M H Koken; F Quignon; M K Chelbi-Alix; L Degos; Z Y Wang; Z Chen; H de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 4.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

5.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

Authors:  David Grimwade; Jelena V Jovanovic; Robert K Hills; Elizabeth A Nugent; Yashma Patel; Rajinder Flora; Daniela Diverio; Katy Jones; Hannah Aslett; Elaine Batson; Kristian Rennie; Roger Angell; Richard E Clark; Ellen Solomon; Francesco Lo-Coco; Keith Wheatley; Alan K Burnett
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

6.  Liquid bead array technology in the detection of common translocations in acute and chronic leukemias.

Authors:  Rodney E Shackelford; Keith D Jackson; Michael J Hafez; Christopher D Gocke
Journal:  Methods Mol Biol       Date:  2013

7.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

8.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

Review 9.  Acute promyelocytic leukemia.

Authors:  R P Warrell; H de Thé; Z Y Wang; L Degos
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245

Review 10.  The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia.

Authors:  Karen A Breen; David Grimwade; Beverley J Hunt
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.